In March 2026, CITEST Diagnostics Inc. introduced its latest diagnostic advancements: an expanded portfolio of rapid tests engineered to deliver accessible, reliable, and precise screening for clinical and public health environments worldwide. These solutions combine innovation with user-centric design, empowering healthcare providers to act decisively across diverse settings, from high-throughput hospitals to decentralized community clinics.

Citest’s new rapid tests continue to set a benchmark for speed and simplicity, delivering actionable results in minutes without the need for complex laboratory equipment. The Multiplex Respiratory Antigen Rapid Tests redefine flexibility, allowing for customizable detection of a wide range of respiratory pathogens - including SARS-CoV-2, Influenza A & B, RSV, MP, RhV, HMPV, and multiple HPIV types - in a single swab specimen. For decentralized care, the Influenza A+B Rapid Test (for self-testing) provides individuals with a reliable tool for rapid differential diagnosis using a simple nasal swab.

Expanding beyond respiratory health, Citest addresses critical needs in toxicology and endocrinology. The Hydrocodone (HCD) Rapid Test offers a robust solution for substance abuse screening, detecting hydrocodone in urine at a cutoff concentration of 500 ng/mL. In parallel, the Cortisol (COR) Rapid Test introduces a non-invasive method for the qualitative detection of this key stress biomarker in oral fluid, supporting the diagnosis of various conditions. Further diversifying the portfolio, the Brucella Abortus Antibody Rapid Test provides a vital tool for detecting antibodies against Brucella abortus in whole blood, serum, or plasma, aiding in the diagnosis of this significant infectious disease.

Citest's expanded rapid test portfolio combines market relevance with unmatched versatility. These kits are designed to thrive in both well-equipped labs and resource-limited environments, eliminating barriers to timely diagnosis. With options ranging from single-use self-tests to high-throughput 25-test packs, and formats including cassettes, devices, and dipsticks, Citest ensures that precision and convenience are always within reach.

Ultimately, Citest's 2026 diagnostic selections stand out for their commitment to user-centric design and broad clinical applicability. By merging customizable multiplexing, portability, and speed, these innovations empower healthcare providers, strengthen public health systems, and solidify Citest's position as a trusted leader in diagnostic excellence.